Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 06.11.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | set forth by specific reference in such filing. Item 5.02 Departure of Directors or Certain Officers; Election of Direct |
| 20.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | a new sentence to the end of paragraph one under Item 5.02 below. All other information in the Initial 8-K remains uncha |
Stammdaten
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Unternehmen & Branche
| Name | Lantheus Holdings, Inc. |
|---|---|
| Ticker | LNTH |
| CIK | 0001521036 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Drug Manufacturers - Specialty & Generic |
| SIC | 2835 · In Vitro & In Vivo Diagnostic Substances |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 5,25 Mrd. USD |
| Beta | -0,13 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 1,541,609,000 | 233,559,000 | 3.41 | 2,227,399,000 | 1,089,797,000 |
| 2025-09-30 | 10-Q | 384,014,000 | 27,771,000 | 0.41 | 2,276,400,000 | 1,119,206,000 |
| 2025-06-30 | 10-Q | 378,045,000 | 78,755,000 | 1.12 | 2,116,077,000 | 1,166,783,000 |
| 2025-03-31 | 10-Q | 372,764,000 | 72,945,000 | 1.02 | 2,055,224,000 | 1,164,194,000 |
| 2024-12-31 | 10-K | 1,533,910,000 | 312,442,000 | 4.36 | 1,980,340,000 | 1,088,011,000 |
| 2024-09-30 | 10-Q | 378,734,000 | 131,093,000 | 1.79 | 2,049,630,000 | 1,179,708,000 |
| 2024-06-30 | 10-Q | 394,091,000 | 62,073,000 | 0.88 | 1,939,831,000 | 1,026,685,000 |
| 2024-03-31 | 10-Q | 369,975,000 | 131,066,000 | 1.87 | 1,831,334,000 | 945,540,000 |
| 2023-12-31 | 10-K | 1,296,429,000 | 326,661,000 | 4.65 | 1,651,149,000 | 815,892,000 |
| 2023-09-30 | 10-Q | 319,946,000 | 131,957,000 | 1.88 | 1,521,610,000 | 698,759,000 |
| 2023-06-30 | 10-Q | 321,700,000 | 94,131,000 | 1.33 | 1,337,720,000 | 552,645,000 |
| 2023-03-31 | 10-Q | 300,784,000 | -2,807,000 | -0.04 | 1,349,284,000 | 445,516,000 |
| 2022-12-31 | 10-K | 935,061,000 | 28,067,000 | 0.40 | 1,321,258,000 | 447,147,000 |
| 2022-09-30 | 10-Q | 239,292,000 | 61,232,000 | 0.86 | 1,095,938,000 | 638,050,000 |
| 2022-06-30 | 10-Q | 223,723,000 | 43,058,000 | 0.61 | 1,013,824,000 | 567,332,000 |
| 2022-03-31 | 10-Q | 208,880,000 | 42,962,000 | 0.61 | 933,166,000 | 515,850,000 |
| 2021-12-31 | 10-K | 425,208,000 | -71,279,000 | -1.06 | 863,784,000 | 464,439,000 |
| 2021-09-30 | 10-Q | 102,073,000 | -13,415,000 | -0.20 | 847,816,000 | 499,344,000 |
| 2021-06-30 | 10-Q | 101,064,000 | -26,657,000 | -0.39 | 857,802,000 | 508,140,000 |
| 2021-03-31 | 10-Q | 92,509,000 | 9,008,000 | 0.13 | 843,448,000 | 528,119,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-08-20 | PATEL RAJIV A | Open Market Sale | -3,365,000 | 56.15 | -188,944,750.00 | -678,6% | ||
| 2025-08-20 | FARALLON PARTNERS L L C/CA | 10% Owner | Open Market Sale | -3,365,000 | 56.15 | -188,944,750.00 | -678,6% | |
| 2025-08-19 | PATEL RAJIV A | Open Market Sale | -41,000 | 55.34 | -2,268,940.00 | -8,1% | ||
| 2025-08-19 | FARALLON PARTNERS L L C/CA | 10% Owner | Open Market Sale | -41,000 | 55.34 | -2,268,940.00 | -8,1% | |
| 2025-08-13 | Blanchfield Paul | Officer, President | Open Market Sale | -3,060 | 53.57 | -163,924.20 | -0,6% | |
| 2025-06-13 | Niedzwiecki Daniel | Officer, See Remarks | Open Market Sale | -6,000 | 78.74 | -472,440.00 | -1,7% | |
| 2025-06-09 | Marshall Robert J. Jr. | Officer, CFO and Treasurer | Open Market Sale | -27,036 | 83.40 | -2,254,767.25 | -8,1% | |
| 2025-06-09 | McHugh Julie | Director | Open Market Sale | -5,192 | 81.62 | -423,771.04 | -1,5% | |
| 2025-06-09 | Marshall Robert J. Jr. | Officer, CFO and Treasurer | Open Market Sale | -3,494 | 81.27 | -283,959.83 | -1,0% | |
| 2025-06-09 | Marshall Robert J. Jr. | Officer, CFO and Treasurer | Open Market Sale | -9,243 | 82.50 | -762,568.76 | -2,7% | |
| 2025-06-05 | Blanchfield Paul | Officer, President | Open Market Sale | -6,599 | 79.65 | -525,610.35 | -1,9% | |
| 2025-06-05 | Niedzwiecki Daniel | Officer, See Remarks | Open Market Sale | -6,000 | 79.65 | -477,900.00 | -1,7% | |
| 2025-06-02 | Heino Mary Anne | Director | Open Market Sale | -3,140 | 74.90 | -235,198.25 | -0,8% | |
| 2025-06-02 | Heino Mary Anne | Director | Open Market Sale | -22,926 | 77.09 | -1,767,372.22 | -6,3% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.